Pulmonx (Pulmonx) Change In Receivables

: $-3.10 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

Pulmonx's change in receivables for the quarter that ended in Dec. 2023 was $-1.76 Mil. It means Pulmonx's Accounts Receivable increased by $1.76 Mil from Sep. 2023 to Dec. 2023 .

Pulmonx's change in receivables for the fiscal year that ended in Dec. 2023 was $-3.10 Mil. It means Pulmonx's Accounts Receivable increased by $3.10 Mil from Dec. 2022 to Dec. 2023 .

Pulmonx's Accounts Receivable for the quarter that ended in Dec. 2023 was $12.11 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Pulmonx's Days Sales Outstanding for the three months ended in Dec. 2023 was 57.30.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Pulmonx's liquidation value for the three months ended in Dec. 2023 was $75.09 Mil.

Pulmonx Change In Receivables Historical Data

The historical data trend for Pulmonx's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulmonx Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

-2.52

1.46

-2.43

-2.19

-3.10

Pulmonx Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Receivables																-1.28	0.53	-0.72	-1.16	-1.76

Pulmonx Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.10 Mil.

Pulmonx (NAS:LUNG) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Pulmonx's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	12.105	/	19.278	*	91
=	57.30

2. In Ben Graham's calculation of liquidation value, Pulmonx's accounts receivable are only considered to be worth 75% of book value:

Pulmonx's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	117.102	-	59.466	+	0.75 * 12.105	+	0.5 * 16.743
=	75.09

Pulmonx Change In Receivables Related Terms

Thank you for viewing the detailed overview of Pulmonx's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Pulmonx (Pulmonx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulmonx Corp (NAS:LUNG) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

4NI:Germany

Address

700 Chesapeake Drive, Redwood, CA, USA, 94063

Website

https://www.pulmonx.com

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.

Executives

French Glendon E. Iii	director, officer: President and CEO	700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Geoffrey Beran Rose	officer: Chief Commercial Officer	5124 ROCKWOOD PARKWAY NW, WASHINGTON DC 20016
John Mckune	officer: Interim CFO	46668 CRAWFORD CT., FREMONT CA 94539
David Aaron Lehman	officer: General Counsel	C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Derrick Sung	officer: Chief Financial Officer	C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 380, SAN FRANCISCO CA 94103
Alissa Hsu Lynch	director	700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Richard M Ferrari	director	2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Tiffany Sullivan	director	700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Boston Scientific Corp	10 percent owner	300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Daniel P Florin	director	56 E. BELL DRIVE, WARSAW IN 46581
Mead Dana G Jr.	director	2750 SAND HILL ROAD, MENLO PARK CA 94025
Thomas William Burns	director	C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Georgia Melenikiotou	director	C/O INSPIRE MEDICAL SYSTEMS, INC., 5500 WAYZATA BOULEVARD, SUITE 1600, GOLDEN VALLEY MN 55416
Staffan Lindstrand	director	C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51